Consequences of latent cytomegalovirus (CMV) infection reactivation on ulcerative colitis flare, as a flare-worsening factor or simple bystander, are debated. Theoretically, CMV-specific cell-mediate immune response will further categorize the patients into high or low risk of CMV colitis. The investigators thus evaluate the usefulness of CMV-specific ELISPOT assay in patient with ulcerative colitis flare to assess the the impact of CMV colitis on ulcerative colitis flare.
Moderate to severe ulcerative colitis patients admitted in Inflammatory Bowel Disease (IBD) center will be enrolled in this study. Eligible patients had active UC with a Mayo score of 6-12 points (moderate or severe disease activity). The investigators will evaluate whether CMV-specific cell-mediated immune response at admission will predict the risk of active cytomegalovirus infection (true pathogen versus bystander).
Study Type
OBSERVATIONAL
Enrollment
80
Asan Medical Center
Seoul, South Korea
CMV infection
CMV colitis (CMV disease involving the colon) was diagnosed by colonic tissue polymerase chain reaction (PCR) or immunohistochemistry (IHC) in accordance with current European guidelines
Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Viral clearance from colonic mucosa
Viral clearance from colonic mucosa was diagnosed as negative by immunohistochemistry (IHC) after a ganciclovir treatment
Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Breakthrough CMV infection
Breakthrough CMV colitis was diagnosed by newly positive colonic tissue polymerase chain reaction (PCR) or immunohistochemistry (IHC) at the time of second colonic biopsy
Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.